Cancer Clinical Trials
Clinical Research
Cancer clinical trials are at the heart of all treatment advances and are key to developing new methods to prevent, detect, and treat cancer. It is through clinical studies that researchers can determine whether new treatments are safe, effective, and if they work better than what is currently available to patients. When you take part in a clinical trial, you add to knowledge about cancer and help improve cancer care for yourself and others.
The Bassett Cancer Institute has been providing access to cutting edge treatments in a convenient, local setting for over 40 years. Bassett Healthcare Network's membership in the Eastern Cooperative Oncology Group (ECOG) allows access to numerous clinical trials through the Clinical Trials Support Unit (CTSU), funded by The National Institutes of Health (NIH) and The National Cancer Institutes (NCI).
Why Should I Consider a Clinical Trial?
Clinical trials are voluntary. Participants receive high-quality care that experts believe may have the potential to become a new standard of cancer treatment. Treatments might be new drugs or new combinations of drugs, new devices, or new ways to use existing treatments. When patients participate in a clinical trial, they are contributing to research that could bring new treatments one step closer to reaching patients across the nation.
ACT (About Clinical Trials) is a great resource for patients considering participation in a clinical trial. The experts and participants in these videos help educate about clinical trials, including what questions to ask about available treatment options, what to consider before participating in a trial, and how to know if a particular trial may be a good option for you.
If you are interested in more information about clinical trials, please call the Bassett Medical Center Clinical Trials office at (607) 547-3089.
Cancer Clinical Trials at Bassett Healthcare Network
Available Clinical Studies
Learn more about our current clinical studies:
CTP-SCC-03
A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma.
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT05323253
(Project 1954534)
Timothy Korytko, M.D.
CCTG MA.39
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03488693
(Project 1525614)
Timothy Korytko, M.D.
S1703
A Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Markers Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03723928
(Project 1350363)
Jeffrey Allerton, M.D.
NRG-BR007
A Phase III Clinical Trial Evaluating Deescalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ≤ 18 Breast Cancer
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT04852887
(Project 1838252)
Timothy Korytko, M.D.
A031704
Active, but closed to accrual.
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03793166
(Project 1442850)
Jeffrey Allerton, M.D.
LUNGMAP
Active, but closed to accrual.
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT03851445
(Project 1368750)
Jeffrey Allerton, M.D.
S1900E
Active, but closed to accrual.
A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT04625647
(Project 1745730)
Jeffrey Allerton, M.D.
S1900K
Active, but closed to accrual.
A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT06031688
(Project 2158744)
Jeffrey Allerton, M.D.
S1914
Active, but closed to accrual.
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT04214262
(Project 1968226)
Jeffrey Allerton, M.D.
A151216
Active, but closed to accrual.
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT02194738
(Project 1246946)
Jeffrey Allerton, M.D.
A081801
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT04267848
(Project 1627574)
Jeffrey Allerton, M.D.
NRG-GU009
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT04513717
(Project 2267195)
Timothy Korytko, M.D.
NRG-GU010
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT05050084
(Project 2267264)
Timothy Korytko, M.D.
CTP-SCC-03
A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients with Recurrent Cutaneous Squamous Cell Carcinoma
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT05323253
(Project 1954534)
Timothy Korytko, M.D.
A211901
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
For more information regarding this trial, visit the ClinicalTrials.gov Identifier:
NCT05008848
(Project 2282138)
Timothy Korytko, M.D.
Call or Email to Learn More About Participating in a Clinical Trial
Call our specialists at (607) 547-3089, or email us at cancerclinicaltrials@bassett.org to learn more about participating in a cancer clinical trial.
Bassett Healthcare Network’s Cancer Treatment Center offers Cancer Clinical Trials in Central New York, including Cooperstown, Oneonta, Cobleskill, and Herkimer.
Related Locations
Hospitals
Bassett Medical Center
1 Atwell Road
Cooperstown, NY 13326-1394
Phone: (607) 547-3456
